CSV October 19, 2023 through October 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
THE	2. METHOD DE	*Second*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	VELOPMENT	*Supplement to USP43–NF38*						of *2.4 Study Design/2.4.1 Time Points*: Change *Assessment of Drug Product Performance—Bioavailability, Bioequivalence, and Dissolution* ?1090?. to: *Assessment of Solid Oral Drug Product Performance and Interchangeability, Bioavailability, Bioequivalence, and Dissolution* ?1090?.
RESIDUAL SOLVENTS—VERIFICATION OF COMPENDIAL PROCEDURES AND VALIDATION OF ALTERNATIVE	VERIFICATION OF COMPENDIAL PROCEDURES	*USP43–NF38*	8404	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Limit Procedures: Procedure A and Procedure B/Verification when solvents likely to be present (LTBP) are not known/S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROCEDURES								*pecificity*: Change or acetonitrile and *cis* -dichloroethene to: or methylisobutylketone and *cis* -dichloroethene
TIAMULIN	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	4368	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the equation in *Analysis*: Change Result = (r_U/r_T) x 100 to: Result = (r_U/r_T) x *D* x 100 AND Add *D* = dilution factor for the *Sample solution*, 0.01
ORBIFLOXACIN	*Related compounds*	*USP43–NF38*	3275	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Procedure*: Change $20{,}000(C_S)(r_i/r_S)(1/F)$ in which C_S is the concentration,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in mg per mL, of orbifloxacin in the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the orbifloxacin peak obtained from the *Standard solution*; and *F* is the relative response factor for each impurity, as presented in *Table 1*. to: $20{,}000(C_S)(r_i/r_S)(1/F)(1/W)$ in which C_S is the concentration, in mg per mL, of orbifloxacin in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the orbifloxacin peak obtained from the *Standard solution*; *F* is the relative response factor for each impurity, as presented in *Table 1*; and *W* is the sample weight taken to prepare the *Test solution* (mg).
MEBENDAZOLE ORAL SUSPENSION	*Identification*	*USP43–NF38*	2744	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change Mix a quantity of Oral Suspension, equivalent to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and 96 percent formic acid (19:1). Proceed as directed for *Identification* under *Mebendazole Tablets*, beginning with “Warm the suspension on a water bath for a few minutes.” The specified result is obtained. to: Mix a quantity of Oral Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								96 percent formic acid (19:1). Warm the suspension on a water bath for a few minutes, cool, and filter through a medium-porosity, sintered-glass filter. Apply 10 ?L of this solution and 10 ?L of a *Standard solution* of USP Mebendazole RS in a mixture of chloroform and 96 percent formic acid (19:1) containing 10 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* <621>) coated

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with a 0.25-mm layer of chromatographic silica gel mixture. Allow the spots to dry, and develop the chromatogram in a solvent system consisting of a mixture of chloroform, methanol, and 96 percent formic acid (90:5:5) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, allow the solvent to evaporate, and examine the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate under shor t-wavelength UV light: the R_F value of the principal spot obtained from the *Test solution* corresponds to that obtained from the *Standard solution*.
TRYPSIN	CHEMICAL INFORMATION	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change $C_{1012}H_{1555}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin) to: $C_{1012}H_{1585}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin)
MIRTAZAPINE TABLETS	ADDITIONAL R EQUIREMENT S	*USP43–NF38*	2978	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Mirtazapine Resolution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MIRTAZAPINE	ADDITIONAL R	*USP43–NF38*	2976	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Mixture RS: Change This resolution mixture contains approximately 0.1% w/w each of the following: Impurity A: 1,2, 3,4,10,14b-Hex ahydro-2-methyl pyr azino[2,1-*a*]pyri do[2,3-*c*][2]benzazepine 2-oxide. to: Mirtazapine. Impurity A: 1,2, 3,4,10,14b-Hex ahydro-2-methyl pyr azino[2,1-*a*]pyri do[2,3-*c*][2]benzazepine 2-oxide. In *USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	EQUIREMENTS							*Reference Standards* <*11*>/USP Mirtazapine Resolution Mixture RS: Change This resolution mixture contains approximately 0.1% w/w each of the following: Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine 2-oxide. to: Mirtazapine. Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyri do[2,3-*c*][2]benzazepine 2-oxide.
GOSERELIN ACETATE	IM PUR ITIES/*Organic Impurities: Related Compounds*	*Interim Revision Announcement (Official May 01, 2020)*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Table 1*: Change Goserelinare to: Goserelin
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	6. ACCEPTANCE CRITERIA	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In Row 1 of *Table 5* and *Table 6*: Align Times with Acceptance Criteria
TIAGABINE HYDROCHLORIDE	ASSAY/ *Procedure*	*USP43–NF38*	4365	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the *Standard solution*: Change Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent to volume. to: 0.1 mg/mL of USP Tiagabine Hydrochloride RS and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. AND In the *Sample solution*: Change Transfer suitable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of Tiagabine Hydrochloride and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent to volume.
EFAVIRENZ TABLETS	IM PURITIES/*Organic Impurities*	*USP43–NF38*	1591	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the footnotes in *Table 2*: Change [d](*S,E*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. [e](*S,Z*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. to: [d](*S,Z*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. [e](*S,E*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluorometh

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl)-2*H*-3,1-benzoxazin-2-one.
GUIDELINES ON THE ENDOTOXINS TEST	METHOD SUITABILITY	*USP43–NF38*	7665	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In Row 2 of Column 3 of *Table 3*: Change hydrochloride to: hydrochloric acid AND In paragraph 2 of *Method Suitability Testing/ Common Test Interferences*: Change hydrochloride to: hydrochloric acid
AMLODIPINE AND ATORVASTATIN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	265	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATORVASTATIN CALCIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	418	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64
AMIODARONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Amiodarone Related Compound H RS: Change 2-Chloro-*N*,*N*-diethylethanamine. $C_6H_{14}ClN$ 135.64 to: 2-Chloro-*N*,*N*-diethylethanamine hydrochloride. $C_6H_{14}ClN \cdot HCl$ 172.09
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP43–NF38*	414	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-iso propyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2,3-Bis(4-fluorophenyl)-5-isopropyl-4-(phenyl car bamo yl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylca

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rbamoyl)-4,5-bis (4-fluorophenyl) -2 -iso propyl-1*H* -pyrrol-1-yl]-3,5-dihydroxyhepta noic acid, calcium salt. AND In USP Atorvastatin Related Compound D RS: Change Epoxide impurity, or 3-(4 -fluorobenzoyl)-2-isobutyryl-3-p henyl-oxirane-2-carboxylic acid phenylamide. to: 3-(4-Fluorobenz oyl)-2-isobutyryl -*N* ,3-diphenyloxira ne-2-carboxami de; Also known as Epoxide impurity, or 3-(4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-fluorobenzoyl)-2-isobutyryl-3-phenyl-oxirane-2-carboxylic acid phenylamide. AND In USP Atorvastatin Related Compound E RS: Change 3*S*,5*S* Enantiomer, or (3*S*,5*S*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. $C_{66}H_{68}CaF_2N_4O_{10}$ 1155.34 to: Calcium (3*S*,5*S*)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as 3*S*,5*S* Enantiomer, or (3*S*,5*S*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. $C_{66}H_{68}CaF_2N_4O_{10}$ 1155.38 AND In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64 AND In Atorvastatin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	CONTAMINANTS	*USP43–NF38*	5378	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Related Compound I RS: Change 654.81 to: 654.82 Change *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species* and *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species*: to: *Absence of Specified Microorganisms <2022>, Test Procedures,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS	ANALYTICAL METHODS	*USP43–NF38*	7400	30-Oct-2020	1-Nov-2020	*NA*	*NA*	*Test for Absence of Salmonella Species* and *Test for Absence of Escherichia coli:* In *In-Process Control s*/paragraph 2: Change Refer to *Risk Assessment* for discussion on critical process parameters (CPP). to: Refer to *Quality Systems* for discussion on critical process parameters (CPP). AND In *Final Product Release Specifi cations/Dose-Defining Assays* /paragraph 3:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change relay to: rely
CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS	REGULATIONS AND STANDARDS	*USP43–NF38*	7400	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Table 5*/Row 8 of Column 2: Change 221 CFR 1271 to: 21 CFR 1271
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	ADDITIONAL R EQUIREMENT S/*Labeling*	*USP43–NF38*	5378	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In footnote 1: Change 1 mg of -alpha tocopheryl acetate to: 1 mg of *all-rac*-alpha tocopheryl acetate
PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION	POLYETHYLENE TEREPHTHALATE BOTTLES AND POLYETHYLENE TEREPHTHALATE G CONTAINERS	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/ Extracting media*: Change *50 percent alcohol*: Dilute 125 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								alcohol with water to 238 mL, and mix. *25 percent alcohol*: Dilute 125 mL of *50 percent alcohol* with water to 250 mL, and mix. *General procedure*: [Note— Use an *Extracting medium* of *50 percent alcohol* for PET bottles and *25 percent alcohol* for PETG bottles.] to: *Purified Water*: See monograph. *50 percent alcohol*: Dilute 125 mL of alcohol with water to 238 mL, and mix. *25 percent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								alcohol: Dilute 125 mL of *50 percent alcohol* with water to 250 mL, and mix. *n-Heptane* *General procedure*: [Note— Use an *Extracting medium* of *50 percent alcohol* for PET bottles and *25 percent alcohol* for PETG bottles.] AND In four instances in *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Heavy Metals*: Change *Extracting media* to: *Purified Water*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Extracting medium AND In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Ethylene Glycol/Test solution*: Change *Extracting media* to: *Purified Water Extracting medium* AND In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Ethylene Glycol/ Proce dure*/paragraph 1: Change *Extracting media* extract

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Extracting medium to: *Purified Water Extracting medium* AND In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Ethylene Glycol/ Proce dure*/paragraph 2: Change using as the blank the solution from the *Extracting media*: the absorbance of the solution to: using *Purified Water Extracting medium* as the blank: the absorbance of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the solution
VOLUMETRIC APPARATUS	STANDARDS OF ACCURACY	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In paragraph 3: Change and then touched against the wall of the receiving vessel to drain the tips. to: and then touched against the wall of the receiving vessel to drain the pipet tip.
EVALUATION OF PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION WITH RESPECT TO THEIR USER SAFETY IMPACT	6. APPLICABILITY AND APPLICATION OF <661.1>	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *6.2 Application*/*6.2.5 Unaddressed Materials*: Change physiochemical to: physicochemical
LOSS ON IGNITION	INTRODUCTION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In paragraph 3: Change Upon completion of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing. to: Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing accurately.
ANISE OIL	IDENTIFICATION/*A. Chromatographic Identity*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Acceptance criteria/ Chromatographic similarity*: Change [Note—The chromatogram of the *Standard* is similar to the reference

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatogram provided with the lot of being used.] to: [Note—The chromatogram of the *Standard* is similar to the reference chromatogram provided with the lot of USP Anise Oil RS being used.]
CLOMIPHENE CITRATE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E,Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N,N*-diethylethanamine hydrochloride. to: (*E,Z*)-2-[4-(1,2-Diphenylethenyl)phe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								noxy]-*N,N*-diethylethanamine hydrochloride.
OXYGEN 93 PERCENT	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
MEDICAL AIR	IMPURITIES	*USP43–NF38*	100	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
VERAPAMIL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	4604	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Buffer*, *Mobile phase*, and *Chromatographic system*: Proceed as directed in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GELATIN	SPECIFIC TESTS/*Sulfur Dioxide*	*Harmonization (Official May 01, 2020)*	5783	30-Oct-2020	1-Nov-2020	*NA*	*NA*	*Assay*. to: *Buffer* and *Mobile phase*: Prepare as directed in the *Assay*. In three instances in *Analysis*: Change 0.1 M sodium hydroxide to: *Titrant* AND In the equation: Change *M* to: *N* AND In the variable definition list: Change *M* = actual molarity of the *Titrant* (mol/L) to: *N* = actual normality of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GALANTAMINE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	*Titrant* In USP Galantamine Hydrobromide Related Compounds Mixture RS: Change Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4a*H*-benzo[2,3]benzofuro[4,3-*cd*]azepine. $C_{17}H_{19}NO_2$ to: Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4a*H*-benzo[2,3]benzofuro[4,3-*cd*]azepine. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{17}H_{19}NO_2$ 269.34
HYDROXYPROPYL BETADEX	CHEMICAL INFORMATION	*USP43–NF38*	5818	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change [94035-02-6]. to: [128446-35-5].
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/ *Procedure*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Buffer A*: Change monobasic potassium phosphate to: monobasic sodium phosphate
METHYLENE BLUE	CHEMICAL INFORMATION	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride; to: Phenothiazin?5?ium, 3,7?bis(dimethylamino)?, chloride, hydrate (1:1:x); 3,7?Bis(dimethy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lamino)phenothiazin?5?ium chloride hydrate; [122965?43?9]. AND Change Monohydrate [122965-43-9]. to: Monohydrate [67183?68?0].
NATEGLINIDE	CHEMICAL INFORMATION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only. See http://uspnf.com/nateglinide-err-img-20201030 for correction
GALANTAMINE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	2081	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Test 3*/*Apparatus 2*: Change peak vessels to: apex vessels
OXYGEN	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Medical Gases Assay ?413? to: *Impurities Testing in Medical Gases* ?413?
APREPITANT CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	362	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Test 3*/*Apparatus 2*: Change peak vessels. to: apex vessels.
PRAZIQUANTEL TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3650	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *For products for veterinary use*/*Apparatus 2*: Change peak vessels to: apex vessels
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP43–NF38*	875	25-Sep-2020	1-Oct-2020	*NA*	*NA*	In *Mobile phase*: Change 10 g/L of electrophoresis grade sodium dodecyl sulfate in *Solution A*. to: 10 g/L of electrophoresis grade sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dodecyl sulfate in *Solution B*.
CLOMIPHENE CITRATE	IDENTIFICATION/*B.*	*USP43–NF38*	1088	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
DACTINOMYCIN	IDENTIFICATION/*A.*	*USP43–NF38*	1227	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DALFAMPRIDINE	IDENTIFICATION/*A*.	*USP43–NF38*	1228	25-Sep-2020	1-Oct-2020	*NA*	*NA*	197U Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
DESVENLAFAXINE	IDENTIFICATION/*A*.	*USP43–NF38*	1280	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DESVENLAFAXINE SUCCINATE	IDENTIFICATION/*A.*	*USP43–NF38*	1283	25-Sep-2020	1-Oct-2020	*NA*	*NA*	*Spectroscopy*: 197K or 197A Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
ETIDRONATE DISODIUM	IDENTIFICATION/*A.*	*USP43–NF38*	1782	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197? to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*
TELMISARTAN TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	4240	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tests ?197?, *Ultraviolet Spectroscopy*: 197U: to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U:
METAXALONE TABLETS	IMPURITIES	*Revision Bulletin (Official September 01, 2020)*	Online	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Organic Impurities* to: IMPURITIES *Organic Impurities*
AMIODARONE HYDROCHLORIDE	IDENTIFICATION/*A.*	*USP43–NF38*	Online	25-Sep-2020	1-Oct-2020	*NA*	*NA*	This erratum applies to the *USP-NF* online platform only. Change *Infrared Absorption* ?197K? to: *Spectroscopic Identification Tests* ?197?,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Infrared Spectroscopy: 197K

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- …
- Next page Next ›
- Last page Last »